43 Drug Discovery, Pharmaceuticals & Cannabis Testing


GMP-grade stem cell media simplifi es transition to clinical manufacturing


AMSBIO has introduced GMP-grade StemFit® for Differentiation, a chemically defined, animal component-free medium designed for consistent and efficient differentiation of human induced pluripotent stem (hiPS) and embryonic stem (hES) cells. Now compliant with Good Manufacturing Practices (GMP), this formulation supports seamless progression to clinical applications.


By eliminating animal-derived components, StemFit® for Differentiation minimises immunogenic risks while ensuring lot-to-lot consistency. Manufactured under strict GMP guidelines, it provides a reliable solution for the reproducible expansion and differentiation of stem cell- derived tissues in clinical settings.


Dr Satoshi Okamoto of Yokohama City University Graduate School of Medicine noted: “Using StemFit® Basic03 for iPSC culture alongside StemFit® for Differentiation, we established a stable, animal-origin-free protocol.”


By the end of 2025, all StemFit® formulations, including Basic03 and Basic04 CT, along with key proteins such as bFGF and Activin A, will be available exclusively as GMP-grade versions. This transition enables labs to move from research to clinical manufacturing without the need to retest materials or adjust protocols, reducing both complexity and costs.


To make GMP adoption accessible, AMSBIO has optimised manufacturing to minimise cost differences between research and GMP-grade products


Aisha Amari, a stem cell specialist at AMSBIO, commented: “With nearly 1,500 citations and growing use in cell and gene therapy, StemFit® has become a trusted solution for researchers and biotech companies worldwide.” Contact AMSBIO for further details about GMP compliant products and services. More information online: ilmt.co/PL/dYLV and ilmt.co/PL/y5mY


64219pr@reply-direct.com AI-driven platform accelerates drug discovery workfl ows


Sapio Sciences has integrated the NVIDIA BioNeMo platform into its lab informatics platform, enhancing AI-driven computational drug discovery. By embedding BioNeMo within Sapio ELN (Electronic Lab Notebook), researchers can streamline workflows, optimise molecular modelling, and improve decision-making in early-stage drug development.


The integration provides access to powerful AI tools, including AlphaFold2 NIM for protein structure prediction, MoIMIM NIM for small molecule design, and DiffDock NIM for AI-powered molecular docking. These capabilities enable scientists to generate novel candidate molecules, predict protein-ligand interactions, and refine drug targets with greater efficiency.


Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, emphasised the significance of the collaboration: “Researchers often face challenges with fragmented AI tools that slow down innovation. By integrating NVIDIA’s cutting-edge AI models directly into Sapio ELN, we are providing scientists with seamless access to advanced drug discovery capabilities, eliminating inefficiencies and accelerating research.”


Anthony Costa, Director of Digital Biology at NVIDIA, added: “AI is reshaping pharmaceutical research, and this integration ensures that scientists can harness generative AI for faster, more accurate drug development. With BioNeMo’s molecular modelling capabilities now embedded in Sapio’s platform, researchers can optimise drug candidates with unprecedented speed.”


This integration underscores Sapio Sciences’ commitment to advancing biopharmaceutical innovation by leveraging AI to drive data-driven research and accelerate the transition from discovery to development.


More information online: ilmt.co/PL/A7nx 64386pr@reply-direct.com Automated sample prep enhances LC/GC cannabis analysis


Tecan introduces the Resolvex Prep, an ideal solution for automating cannabis analysis workflows while using the same labware as manual processes. This platform offers automated syringe change, a wash station, and the ability to pipette into/out of septa-sealed vials, all while precisely handling solvents used in LC/LCMS and GC/GCMS analysis.


Starting with weighed cannabis flowers, the Resolvex Prep automates the entire sample preparation process of extraction, filtration, and final solution preparation, directly into 2 mL autosampler vials, for subsequent chromatographic analysis.


Recent demonstrations have shown excellent performance compared to the previous GMP-validated manual protocol, achieving THCA concentrations of approximately 25.4% and a recovery rate of 99.1% along with a 97.5% recovery rate for terpenoids, confirming the method’s reliability and efficiency.


The Resolvex Prep is capable of handling a wide range of sample matrices including plants, water and soil. It supports various extraction methods, such as SPE and LLE, enhancing its adaptability for diverse applications.


More information online: ilmt.co/PL/Z6x3 64070pr@reply-direct.com


Multiplexed assay kit advances single-cell selection


Sphere Bio has introduced the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay designed for its next-generation Cyto-Mine® Chroma platform. This innovative solution enhances single-cell selection by integrating antibody productivity and cell viability analysis in a single workflow, streamlining biotherapeutic development.


The Cyto-Mine Chroma platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, or intracellular markers. With the addition of multiplexing capabilities, researchers can now identify high-producing, viable clones more efficiently, reducing workflow times and improving selection accuracy. Early-stage screening helps eliminate non-viable or apoptotic clones, minimising false positives and ensuring only the most productive cells are chosen for downstream applications.


By simultaneously detecting secreted antibodies and assessing cell viability, this assay supports high-throughput screening in a fully automated workflow. Initial data suggest that approximately five percent of selected high-producing clones are apoptotic. Removing these early on reduces development risks and enhances the reliability of the selection process.


The Cyto-Cellect Human IgG Kappa and Viability Assay Kit, combined with Cyto-Mine Chroma, offers significant advantages, including advanced multiplexing for precise selection, streamlined workflows that reduce timelines from months to hours, and improved throughput at lower costs. Additionally, the system provides built-in monoclonality assurance, further strengthening its role in accelerating cell line development.


Sphere Bio’s latest innovation marks an important step in its mission to provide transformative solutions that set new industry benchmarks. Dr Xin Liu, Senior Product Manager for Assays and Applications at Sphere Bio, emphasised that integrating viability assessment with antibody detection significantly enhances single-cell workflows, ensuring the selection of only the healthiest, most productive cells. Dr Maryam Ahmadi, Director of Science at Sphere Bio, highlighted that this launch is the first in a series of multiplex assays designed for the Chroma platform, bringing next- generation analytical capabilities to researchers and advancing biopharmaceutical discovery.


More information online: ilmt.co/PL/v5kq 64387pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56